ConcertAI Integrates TeraRecon to Enhance Healthcare AI

ConcertAI has announced the integration of TeraRecon, a leading medical imaging analysis company, into its operations. This merger is set to create the industry’s first unified AI software-as-a-service (SaaS) company, combining electronic medical records, genomic data, and medical image data into a single, integrated network. The aim is to enhance clinical research and decision support applications, marking a substantial shift in AI innovation within the healthcare sector.

This integration means ConcertAI, known for its enterprise AI and real-world data (RWD) solutions, is advancing artificial intelligence, machine learning, and deep learning innovations from life sciences to full deployment within healthcare provider workflows. 

“Serving 1,300 clinical sites globally, TeraRecon is a Best in KLAS solution provider for radiology, oncology, cardiology, neurology, and vascular surgery,” said Jeff Elton, PhD, CEO of ConcertAI. He emphasized that TeraRecon’s solutions are independent of any one manufacturer’s imaging equipment or PACS system, allowing a unified clinical workflow to enhance efficiencies and deliver actionable insights to physicians.

The integration aims to develop advanced AI-augmented diagnostic and interpretive capabilities, bridging biomedical innovation and care coordination. Much of this progress will be achieved through software-as-a-medical devices, utilizing retrospective images and electronic medical record (EMR) data for model development and validation. 

“The common EurekaAI model development and deployment solution layer will support both innovators and healthcare providers,” stated Dan McSweeney, president of TeraRecon. He noted that the collaboration with ConcertAI will accelerate these innovations, gradually integrating them into standard care as new treatments evolve.

ConcertAI plans to incorporate TeraRecon’s technologies into its Digital Clinical Trials Network, another industry first for digital clinical development solutions, leveraging TeraRecon’s expansive customer base. 

Jeff Elton highlighted that with the FDA’s recent guidance on RWD for regulatory decision-making, ConcertAI stands as the only oncology, hematology, and urology-focused company capable of integrating primary data sources for critical patient response and safety assessments. He projected that all regulatory submissions in oncology would soon integrate real-world evidence, with initial studies already underway using ConcertAI’s network, TeraRecon-analyzed images, and integrated electronic medical data.

Looking ahead, the combined companies will operate clinical, engineering, and commercial locations in Cambridge, MA; Plymouth Meeting, PA; Durham, NC; Frankfurt, Germany; Tokyo, Japan; and Bangalore, India. 

This strategic expansion is expected to significantly transform AI innovation within the healthcare sector, driving forward the integration of AI-augmented diagnosis and treatment capabilities from biomedical innovation to care coordination.